You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

Article metrics

Article menu

Download PDFPDF

XML
Diabetes and endocrinology
Protocol
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

 

Online download statistics by month:

Online download statistics by month: February 2020 to April 2024

AbstractFullPdf
Feb 2020462448122
Mar 2020999737
May 2020444212
Jun 2020575330
Jul 2020383419
Aug 202025246
Sep 2020303010
Oct 2020333213
Nov 202023236
Dec 2020302713
Jan 2021242212
Feb 2021171715
Mar 202129297
Apr 202127276
May 202124248
Jun 2021323117
Jul 202126257
Aug 2021252317
Sep 2021242423
Oct 2021373320
Nov 2021151716
Dec 202125237
Jan 202216158
Feb 202231279
Mar 2022313114
Apr 2022222014
May 2022242314
Jun 2022272610
Jul 202213126
Aug 2022202014
Sep 2022181714
Oct 202215118
Nov 2022141410
Dec 202210102
Jan 202315147
Feb 202317178
Mar 202311107
Apr 202310911
May 2023202015
Jun 202311113
Jul 2023201812
Aug 2023111113
Sep 202315159
Oct 202315153
Nov 202318185
Dec 202323216
Jan 202421205
Feb 202419193
Mar 2024101028
Apr 20242213
Total16251561694